98%
921
2 minutes
20
Objective: To evaluate the efficacy and safety of duloxetine in treatment of osteoarthritis compared with placebo.
Method: We conducted a comprehensive search for pertinent randomized controlled trials (RCTs) across multiple databases, including PubMed, Embase, Scopus, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and Google scholar. These selected RCTs aimed to assess the effectiveness and safety of duloxetine versus a placebo in the management of osteoarthritis (OA). We computed the mean difference (MD) for continuous outcome measures and calculated the risk ratio (RR) for dichotomous outcome measures.
Results: Data from 10 RCT including 2294 participants comparing duloxetine and placebo were pooled. Duloxetine showed improvement in BPI-S (Brief Pain Inventory-Severity)MD = - 0.66; 95% CI, [- 0.75, - 0.57], BPI-I (Brief Pain Inventory-Interference)MD = - 0.59; 95% CI [- 0.66, - 0.52], WOMAC (Western Ontario and McMaster Universities Arthritis Index) pain sub scale scores SMD = - 2.56; 95% CI, [- 4.24, - 0.89] = 0.003; physical function MD = - 4.59; 95% CI, [- 5.83, - 3.34] < 0.00001; SF 36 (Short Form) Physical function MD = 1.56; 95% CI, [0.14, 2.97] = 0.03 and patients global impressions scores SMD = - 0.47; 95% CI, [- 0.62, - 0.32]. Duloxetine resulted in higher number of treatment emergent adverse events RR = 1.34; 95% CI, [1.12,1.61] = 0.002; and discontinuations RR = 2.54; 95%, CI, [1.89, 3.42] < 0.00001. However duloxetine was no different from placebo in improving stiffness and in terms of incidence of serious adverse effects.
Conclusion: Duloxetine demonstrates effectiveness in addressing chronic pain and mitigating the decline in physical function associated with knee osteoarthritis (OA), while maintaining a reasonable level of tolerable adverse events. However, it does not offer a distinct advantage in alleviating joint stiffness.
Supplementary Information: The online version contains supplementary material available at 10.1007/s43465-025-01372-y.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367579 | PMC |
http://dx.doi.org/10.1007/s43465-025-01372-y | DOI Listing |
Stroke
September 2025
Department of Neurology, Yale School of Medicine, New Haven, CT (L.H.S.).
Preclinical stroke research faces a critical translational gap, with animal studies failing to reliably predict clinical efficacy. To address this, the field is moving toward rigorous, multicenter preclinical randomized controlled trials (mpRCTs) that mimic phase 3 clinical trials in several key components. This collective statement, derived from experts involved in mpRCTs, outlines considerations for designing and executing such trials.
View Article and Find Full Text PDFCirc Cardiovasc Interv
September 2025
Keele Cardiovascular Research Group, Keele University, United Kingdom (M.A.M., R.B.).
Background: Evidence informing clinical guidelines assumes that all transcatheter aortic valve implantation (TAVI) devices have similar effectiveness, in other words, displaying a class effect across TAVI valves. We aimed to assess the comparative effectiveness of different TAVI platforms relative to other TAVI counterparts or surgical aortic valve replacement (SAVR).
Methods: MEDLINE/Embase/CENTRAL were searched from inception until April 2025, for randomized controlled trials comparing outcomes with different commercially available TAVI devices relative to other TAVI counterparts or SAVR.
CNS Neurosci Ther
September 2025
College of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, China.
Background: Neurological diseases such as stroke or Parkinson's disease are often accompanied by weakening or loss of proprioception, which seriously affects the motor control ability of the patients. However, proprioception rehabilitation is challenging due to the pain caused by impaired joints and the hard efforts that patients have to make during training. This study investigated the cross-transfer effect of short-term visuomotor training to the untrained wrist from the trained wrist, from both views of behavioral results and brain activity analyses.
View Article and Find Full Text PDFAllergy
September 2025
Institute of Allergology, Charité Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Berlin, Germany.
SYN-53, a multi-strain probiotic food supplement, was recently shown to significantly alleviate allergic rhinoconjunctivitis (ARC) and its symptoms. The diversity and dosage of bacterial strains administered via SYN-53 have been proposed as key drivers of its efficacy. The aim of this study was to assess the role of bacterial diversity and dosage by comparing SYN-53 to a low dose variant (SYN-53-LD), a low diversity variant (SYN-4), and a placebo in the management of ARC.
View Article and Find Full Text PDFMol Nutr Food Res
September 2025
Institute of Nutritional Science, Justus-Liebig University Giessen, Giessen, Germany.
Hypertension represents a major risk factor for cardiovascular diseases. As a diet high in sodium chloride is associated with hypertension, so-called "blood pressure salts" are attracting increasing scientific interest. These are characterized by a partial replacement of sodium chloride by other salts, mainly potassium and magnesium compounds.
View Article and Find Full Text PDF